Rigosertib Sodium
A synthetic benzyl styryl sulfone analogue with potential antineoplastic activity. Polo-like kinase 1 inhibitor ON 01910.Na inhibits polo-like kinase1 (Plk1), inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. This agent may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. [ ]
Term info
Rigosertib Sodium
- ON 01910.Na
- Polo-like kinase 1 Inhibitor ON 01910.Na
- RIGOSERTIB SODIUM
- Rigosertib Sodium
NCIT_C116978, NCIT_C63923, NCIT_C128784, NCIT_C157711, NCIT_C116977, NCIT_C157712
A substance being studied in the treatment of cancer. It blocks certain proteins that are needed for cell growth and may kill cancer cells. ON 01910.Na is a type of protein kinase inhibitor and a type of benzyl styryl sulfone analog.
592542-60-4
C21H24NO8S.Na
CTRP, FDA
Rigosertib Sodium
406FL5G00V
http://purl.obolibrary.org/obo/NCIT_C30006
Polo-like_kinase_1_Inhibitor_ON_01910_Na
573371
573371
Rigosertib Sodium
Pharmacologic Substance
C3467794
C71355
Term relations
- Serine/Threonine Kinase Inhibitor
- Antineoplastic Enzyme Inhibitor
- Chemical_Or_Drug_Has_Physiologic_Effect some Enzyme Inhibition
- Chemical_Or_Drug_Affects_Gene_Product some Serine/Threonine-Protein Kinase PLK1
- Chemical_Or_Drug_Has_Physiologic_Effect some Inhibition of Cell Proliferation
- Chemical_Or_Drug_Has_Physiologic_Effect some Signal Transduction Inhibition